Phosphate supplementation for hypophosphataemia and parenteral nutrition

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 4, Issue 3, 2001, Pages 227-233

  Hicks, William ^a   Hardy, Gil ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b OXFORD BROOKES UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATE;

BONE DISEASE; CHEMISTRY; HUMAN; HYPOPHOSPHATEMIA; NUTRITIONAL REQUIREMENT; PARENTERAL NUTRITION; REVIEW;

BONE DISEASES; HUMANS; HYPOPHOSPHATEMIA; NUTRITIONAL REQUIREMENTS; PARENTERAL NUTRITION; PHOSPHATES;

EID: 0035350558     PISSN: 13631950     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075197-200105000-00010     Document Type: Article

References (49)

1. Harris CA, Baer PG, Chirito E, Dirks JH. Composition of mammalian glomerular filtrate. Am J Physiol 1974; 227:972-976.
2. Barker ES, Singer RB, Elkington JR, Clark JK. The renal response in man to acute experimental alkalosis and acidosis. J Clin Invest 1957; 36:515-529.
3. Ullrich KJ, Rumrich G, Kloss S. Phosphate transport in the proximal convolution of the rat kidney: effect of the extracellular and intracellular pH. Pflügers Arch 1978; 337:33-42.
4. Lichtman MA, Miller DR, Cohen J, Waterhouse C. Reduced red cell glycolysis, 2,3-diphosphoglycerate and adenosine triphosphate concentration and increased haemoglobin-oxygen affinity caused by hypophosphataemia. Ann Intern Med 1971; 74:562-568.
5. Kruse JA, Al-Douahji M, Carlson RW. Hypophosphataemia in critically ill patients: incidence and associations [Abstract]. Crit Care Med 1992; 20:104.
6. Paleologos M, Stone E, Braude S. Persistent, progressive hypophosphataemia after voluntary hyperventilation. Clin Sci 2000; 98:619-625. This important study documents the significant fall in serum phosphate as a result of hyperventilation.
7. Lewis JF, Hodsman AB, Driedger AA, et al. Hypophosphataemia and respiratory failure: prolonged abnormal energy metabolism demonstrated by magnetic resonance spectroscopy. Am Med J 1987; 83:1139-1143.
8. Haglin L, Burman LA, Nilsson M. High prevalence of hypophosphataemia amongst patients with infectious diseases. A retrospective study. J Intern Med 1999; 246:1:45-52. This useful retrospective study analysed the potential for phosphate supplementation in patients with infectious diseases.
9. Chines A, Pacifice R. Antacid and sucralfate induced hypophosphataemic osteomalacia: a case report and review of the literature. Calcified Tissue Int 1990; 47:291-295.
10. Bugg NC, Jones JA. Hypophosphataemia; pathophysiology, effects and management on the intensive care unit. Anaesthesia 1998; 53:895-902.
11. Body JJ, Cryer PE, Offord KP, Heath H. Epinephrine is a hypophosphataemic hormone in man. J Clin Invest 1983; 71:572-578.
12. Eisenbrey AB, Mathew R, Kiechles FL. Mannitol interference in an automated serum phosphate assay. Clin Chem 1987; 27:161-162.
13. Smit AJ, Meijer S, Wesseling H, et al. Impaired renal haemodynamic but conserved naturetic response to dopamine in patients with renal disease. Nephron 1989; 52:338-346.
14. Dawson DJ, Babbs C, Warnes TW, Neary RH. Hypophosphataemia in acute liver failure. Br Med J 1987; 295:1312-1313.
15. Eckardt KU, William C, Frei U. Severe hypophosphataemia in paracetamol-induced oliguric renal failure. Nephrol Dial Transplant 1999; 14:8:2013-2014.
16. Esmail MM, Prasad S, Mahon SV, Waters B. Difficulty in weaning a patient with diabetic ketoacidosis from a ventilator: an association with hypophosphataemia. Br J Int Care 2000; 10:30-32. An interesting case report of hypophosphataemia in the ICU is presented.
17. Szabo A, Tulassay T, Korner A, et al. Change of serum inorganic phosphate complexes in diabetic ketoacidosis. Clin Physiol Biochem 1989; 7:93-96.
18. Crook M. Phosphate: an abnormal anion? Br Med J 1994; 52:200-203.
19. Mostella ME, Tuttle EP. Effects of alkalosis on plasma concentration and urinary excretion of inorganic phosphate in man. J Clin Invest 1964; 43:138-149.
20. Zazzo JF, Troche G, Ruel P, Maintenant J. High incidence of hypophosphataemia in surgical intensive care patients: effect of phosphorous therapy on myocardial function. Intensive Care Med 1995; 21:826-831.
21. Buchman AC, Moukarzel A. Metabolic bone disease associated with total parenteral nutrition. Clin Nutr 2000; 19:4:217-231. This is a comprehensive review of the many factors, including phosphate deficiency, that contribute to bone disease in PN patients.
22. Pironi L, Marselli Labate AM, Pertkiewicz M, et al., ESPEN-HAN working group. Prevalence of bone disease in home parenteral nutrition [Abstract]. Clin Nutr 2000; 19:19.
23. Raupp P, von Kries R, Pfahl H, Manz F. Glycero-vs glucose-phosphate in parenteral nutrition of premature infants: a comparative in vitro evaluation of calcium/phosphorous compatibility. JPEN J Parenter Enteral Nutr 1991; 15:469-473.
24. Lumpkin MM. Safety alert: hazards of precipitation associated with parenteral nutrition. Am J Hosp Pharm 1994; 51:1427-1428.
25. Bertch KE, McKinnon BT. Pharmaceutical issues for parenteral nutrition solutions. In: Nutrition support pharmacy: selected cases for self-study. Cristensen ML, McKinnon BT (editors). Silver Spring, MD: American Society of Parenteral and Enteral Nutrition; 1995. pp. 7-1-7-16.
26. McKinnon BT. FDA safety alert: hazards of precipitation associated with parenteral nutrition. Nutr Clin Pract 1996; 11:59-65.
27. Driscoll DF, Newton DW, Bistrian BR. Precipitation of calcium phosphate from parenteral nutrient fluids. Am J Hosp Pharm 1994; 51:2834-2836.
28. Hardy G, Ball P, McElroy B. Basic principles for compounding all-in-one parenteral nutrition admixtures. Curr Opin Clin Nutr Metab Care 1998; 1:291-296.
29. Mirtallo JM. The complexity of mixing calcium and phosphate. Am J Hosp Pharm 1994; 51:1535-1536.
30. Kimura S, Nose O, Seino Y, et al. Affects of alternate and simultaneous administrations of calcium and phosphorus on calcium metabolism in children receiving total parenteral nutrition. JPEN J Parenter Enteral Nutr 1986; 10:513-516.
31. Mo-Suwan L, Puetpaiboon A, Apiromrak B. Calcium and phosphate solubility curves for parenteral nutrient solutions containing Vaminolact. J Med Assoc Thai 1997; 80:516-520.
32. Ronchera CL, Jiminez V, Piedro J. Stability of parenteral nutrition mixtures containing organic phosphates. Clin Nutr 1995; 14:373-380.
33. Tormo C, Ronchera CL, Parra V, Jimenez V. Organic vs inorganic phosphate administration in total parenteral nutrition: the source matters [Abstract]. Clin Nutr 1994; 13:57.
34. Devlieger H, de Pourq L, Casneuf A, et al. Standard two-compartmental formulation for TPN in the neonatal intensive care unit: a fluid tolerance based system. Clin Nutr 1993; 12:282-286.
35. Ronchera CL, Allwood MC, Hardy G. Organic phosphates in parenteral nutrition. Pouring fresh water into an old bucket. Nutrition 1996; 12:388-389.
36. Hardy G, Davies C. Stability of TPN mixtures incorporating glucose-1-phosphate [Abtract]. Clin Nutr 1987; 6:50.
37. Costello I, Powell C, Williams AF. Sodium glycerophosphate in the treatment of neonatal hypophosphataemia. Arch Dis Child Fetal Neonatal Ed 1995; 73:F44-F45.
38. Sargent JD, Dalton MA, O'Connor GT, et al. Randomized trial of calcium glycerophosphate-supplemented infant formula to prevent lead absorption. Am J Clin Nutr 1999; 69:1224-1230.
39. 2+ transport ATPase. J Neurochem 1999; 72:81-86.
40. Cohly HH, Stephens JW, Angel MF, et al. The role of fructose-1,6-diphosphate in cell migration and proliferation in an in vitro xenograft blood vessel model of vascular wound healing. In Vitro Cell Dev Biol Anim 1999; 35:510-514.
41. Chien S, Zhang F, Niu W, et al. Fructose-1,6-diphosphate and a glucose-free solution enhances functional recovery in hypothermic heart preservation. J Heart Lung Transplant 2000; 19:277-285.
42. Niu W, Zhang F, Ehringer W, et al. Enhancement of hypothermic heart preservation with fructose 1,6-diphosphate. J Surg Res 1999; 85:120-129.
43. Colonna F, Candusso M, De Vonderweid U, et al. Calcium and phosphorous balance in very low birth weight babies on total parenteral nutrition. Clin Nutr 1990; 9:89-95.
44. Markov AK, Neely WA, Didlake RH, et al. Metabolic responses to fructose-1,6-diphosphate in healthy subjects. Metabolism 2000; 49:698-703. This is a good review of FDP metabolism.
45. Valerio G, Chiapparelli M, Cassano A. Effects of fructose-1,6-diphosphate in patients with chronic respiratory failure and hypophosphoraemia. Ital J Chest Dis 1990; 44:295-299.
46. Marchesani F, Valerio G, Dardes N, et al. Effect of intravenous fructose-1,6-diphosphate administration in malnourished chronic obstructive pulmonary disease patients with chronic respiratory failure. Respiration 2000; 67:177-182. This paper presents a novel pharmacological use of FDP in chronic obstructive pulmonary disease patients that requires further investigation.
47. Prinzivalli M, Ceccarelli S. Sodium D-fructose-1,6-diphosphate vs. sodium monohydrogen phosphate in total parenteral nutrition: a comparative in vitro assessment of calcium phosphate compatibility. JPEN J Parenter Enteral Nutr 1999; 23:326-332. This comprehensive stability study compared inorganic phosphate with FDP under different conditions, with helpful stability curves and comments on clinical significance.
48. Hicks W, Hardy G. Stability of FDP in calcium containing total parenteral nutrition mixtures. Proc Nutr Soc 2001 (in press).
49. Tartari S, Vivarelli R, Garutti G. Blood phosphorous levels and phosphorous balance during infusion of Fructose-1,6-diphosphate in parenteral nutrition. Riv Ital Nutr Parent Ent 1989; 7:69-73.